Insider trade

Cns Pharmaceuticals (CNSP): CEO received 9,761 units

John M Climaco, CEO at Cns Pharmaceuticals, reported a grant / award of 9,761 units.

9,761
Derivative units
Traded
Nov 17, 2025
Filed
Nov 19, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Nov 17, 2025Company filing · Form 8-K · Executive change, Bylaws or charterChanged a top executive or board member, and changed its bylaws, charter or fiscal year (and 1 more item)“As reported below under Item 5.07 of this Current Report, CNS Pharmaceuticals, Inc. (the “Company”) held its scheduled 2025 Annual Meeting of Stockholders (the “Annual Meeting”) at which the Company’s stockholders approved amendments to the Company's 2020 Equity Plan (the “2020 Plan”) including an increase in the number of shares of common stock, par value $0.001 per share, authorized for issuance under the 2020…”

What came next

  1. Dec 16, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 16, 2025, CNS Pharmaceuticals, Inc. (the “Company”) entered into an employment agreement (the “Employment Agreement”) with Rami Levin to serve as the Company’s Chief Executive Officer and President effective January 1, 2026.”
  2. Feb 10, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On February 10, 2026, CNS Pharmaceuticals, Inc. (the “Company”) entered into an employment agreement (the “O’Loughlin Employment Agreement”) with Steve O’Loughlin to serve as the Company’s Chief Financial Officer effective March 2, 2026.”
  3. Feb 26, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On February 26, 2026, CNS Pharmaceuticals, Inc. (the “Company”) entered into an employment agreement (the “Employment Agreement”) with Lynne Kelley to serve as the Company’s Chief Medical Officer effective March 2, 2026.”
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Cns Pharmaceuticals

OQRO holds no insider, Congress, fund or contract record for Cns Pharmaceuticals dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CNSP page.

How this filing works

Explore the data

Common questions

Which Cns Pharmaceuticals (CNSP) insider traded, and how much?

John M Climaco, CEO at Cns Pharmaceuticals, reported a grant / award of 9,761 units. Not an open-market trade.

When did it happen, and when was it made public?

Traded: Nov 17, 2025. Filed: Nov 19, 2025. That is 2 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

Does this mean CNSP stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Cns Pharmaceuticals

Everything OQRO holds on this company is on its CNSP page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data